- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01519466
Impact of a built-in Insulin Calculator Feature on Diabetes Control - Pilot Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Amsterdam, Nederland, 1007 MB
- VU University Medical Centre (VUMC)
-
-
-
-
-
Bad Mergentheim, Tyskland, 97980
- Diabetes Zentrum Mergentheim
-
Hannover, Tyskland, 30173
- Diabetes-Zentrum für Kinder und Jugendliche
-
Ulm, Tyskland, D-89081
- Institut für Diabetes - Technology Forschungs - und Entwicklungsgesellschaft mbH an der Universität Ulm
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subject with Type 1 diabetes on MDI (3 or more insulin injections per day (U100 insulin)) for at least 1 year and insulin adjusting
- HbA1c between 7.0% and 9.5% (53 to 80 mmol/mol) inclusive
- Age 18 and over
- In the investigator's opinion, thought technically capable of using masked CGM
- Subject self reporting a minimum of 21 SMBG tests per week prior to study enrolment
- Willing to perform a minimum of 4 SMBG tests per day during study
Exclusion Criteria:
- Subject has any concomitant disease or condition that, in the investigator's opinion, may compromise patient safety
- Subject is participating in another study of a glucose monitoring device / drug that could affect glucose measurements / management
- Subject is pregnant / planning to become pregnant within the planned study timeline
- Subject is known to require a dose of more than 50 units of U100 insulin in any one bolus injection
- Subject is currently on an insulin pump
- Subject is currently using the FreeStyle InsuLinx
- Subject is currently using the FreeStyle Freedom Lite
- Subject is currently using CGM
- Subject has an allergy to medical grade adhesives
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Støttende omsorg
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: Intervention
Subjects will use a FreeStyle InsuLinx blood glucose meter during the study
|
FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
|
Annen: Control
Subjects will use a FreeStyle Freedom Lite blood glucose meter during the study.
|
FreeStyle Freedom Lite is a blood glucose meter
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Time in Target Blood Glucose Range
Tidsramme: Day 1-15 compared with Day 60-74
|
Masked continuous glucose monitoring data will be collected for two weeks at the start of the study and 2 weeks at the end of the study.
Analysis will assess the difference between the assessment and baseline phase for the intervention group.
Target blood glucose range is 3.9 to 10.0mmol/l (70 to 180mg/dL)
|
Day 1-15 compared with Day 60-74
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
HbA1c
Tidsramme: Day 1 compared with Day 74
|
HbA1c will be tested at baseline (day 1) and then again at end of study (approximately day 74). The percentage of glycosylated hemoglobin in Diabetes Control and Complications Trial (DCCT) units was standardized to the newer International Federation of Clinical Chemistry (IFCC) units (mmol/mol). |
Day 1 compared with Day 74
|
Change in Diabetes Treatment Satisfaction Questionnaire (DTSQc) Scores From Day 1 to Day 60.
Tidsramme: Day 60 compared to day 1
|
The Diabetes Treatment Satisfaction Questionnaire change (DTSQc) score is used to assess relative change in participant satisfaction from baseline. The questionnaire consists of 8 items, 6 of which (1 and 4 through 8) assess treatment satisfaction. Each item is rated on a 7-point Likert scale (-3 to +3). The scores from the 6 treatment satisfaction items are summed to a Total Treatment Satisfaction Score, which ranges from -18 (much less satisfied) to +18 (much more satisfied). There is one question to assess the change in satisfaction with perceived frequency of Hypoglycaemia and one question to assess change satisfaction with perceived frequency of Hyperglycaemia. Each question is rated on a 7-point Likert scale (-3 to +3), -3 (much less satisfied) to +3 (much more satisfied). The 95% confidence intervals for the FreeStyle InsuLinx group DTSQc scores was calculated using a one-sample t-test. |
Day 60 compared to day 1
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Prof. Michaela Diamant, VU University Medical Centre (VUMC)
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- ADC-PMR-INX-11012
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Type 1 diabetes
-
Oxford Brookes UniversityUniversity of OxfordFullførtFysisk aktivitet | Mental helse velvære 1 | Kognitiv funksjon 1, sosial | Academic Attainment | Fitness TestingStorbritannia
-
IpsenAvsluttet
-
Merck Sharp & Dohme LLCRekrutteringIkke-småcellet lungekreft | Solide svulster | Programmert celledød-1 (PD1, PD-1) | Programmert celledød 1 ligand 1 (PDL1, PD-L1) | Programmert celledød 1 ligand 2 (PDL2, PD-L2)Japan
-
Rambam Health Care CampusIsrael Science FoundationFullført
-
Alvotech Swiss AGFullført
-
PfizerFullført
-
Stony Brook UniversityFullført
-
SanionaFullført
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionFullført
-
Calliditas Therapeutics ABFullført
Kliniske studier på FreeStyle InsuLinx
-
Abbott Diabetes CareFullførtSukkersykeStorbritannia